medigraphic.com
Academia Mexicana de Neurología, A.C.

2011, Number 1

<< Back Next >>

Rev Mex Neuroci 2011; 12 (1)

Recomendation and treatment aplication of partial seizures with oxcarbazepine. National survey of Mexican neurologists

Alva ME, López RM, Rogel OFJ, Sevilla CRA, Gómez PCJ, Rodríguez LI, Rodríguez KRJ, Suástegui RRA, Espinoza MR, Genel CMA, Montoya SJG, Gutiérrez MJ

Language: Spanish
References: 20
Page: 8-15
PDF size: 89.82 Kb.


ABSTRACT

Introduction and objectives: Epilepsy seizures present genetic or hereditary aetiology. Genetic causes might be: a) Some malfunctioning in ionic channels. b) Metabolic alterations that distort neuronal structure or c) Modifications in neuronal migration. Based on the type of epilepsy, idiopathic or resistant to treatment, new anti-epileptic drugs are required. Oxcarbazepine appears in Mexico, to be tested in recent international studies according to refractory or partial seizures recently diagnosed. After gathering information on epilepsy in Mexico, it became necessary to know its usefulness and contrast it to the international regulations. Methodology: A 20-option questionnaire was answered by the 11 regional coordinators who were distributed in 8 areas. Proper demographic information from epileptic patients treated with oxcarbazepine was added to the results in order to be analyzed in an individual and general manner. Results: 306 doctors from 35 cities answered this questionnaire: 146 neurologists (48%), 81 neuropaediatricians (26%), 60 neurosurgeons (19.6%), 19 from other specialities (6.4%). The epileptic patients number was 21,476, only 39% of the general medical consultation. 12,646 was partial seizures (58%) treated with oxcarbazepine, or carbamazepine and valproic acid. Crisis control is reached in 78.8%. A 3 to 5-year treatment is followed by a 69.3% and only 10.5% never stops. Conclusions: Oxcarbazepine is the treatment in partial seizures, as considered by most Mexican neurologists. Its length was similar to those reported in medical literature but given in minor doses. The collateral effects were minimal and prevented patients from stopping it. Seizures control in refractory epilepsy is achieved with oxcarbazepine as additional therapy, showing similar results as if managed as monotherapy.


REFERENCES

  1. 1 . Wellington Keri, Goa LKaren. Oxcarbazepine. Actualization about efficacy in management of epilepsia.CNS Drugs 2001; 15(2): 137-63.

  2. Schmidt D, Sachdeo R. Oxcarbazepíne for treatment of partial epilepsy a review and recommendations for clinical use. Epilepsy and Behavior 2000; 1: 396-405.

  3. Guerreriro MM, Vigonius U, Pohlmann H. A doublé blind controlled clinical trial of oxcarbazepine versus phenitoin in children and adolescents with epilepsy. Epilepy Res 1997; 26: 451-60.

  4. Glauser T, Nigro M, Schadeo R. Adjuntive therapy with oxcarbazepine in children with partial seizures. Neurology 2000; 103: 2237-44.

  5. Barcs G, Walker E, Elger CE. Oxcarbazepine- placebo controlled, dose ranging trial in refractory partial epilepsy Epilepsia 2000; 103: 2237-44.

  6. Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R,Baker GA, Chadwick DW. The SANAD study effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine or topiramate for treatment of partial epilepsy: an unblended randomized controlled trial. Lancet 2007; 369: 1000-15.

  7. Schacter SC. Oxcarbazepine: current status and clinical applications. Exp Opin Invest Drugs 1999; 8: 1-10.

  8. Patsalos PN, Stephenson TJ, Krishna S, Alyas AA, Lascelles PT, Wiles CM. Side effects induced by carbamazepine-10-11 epoxide. Lancet 1985; 2: 1432.

  9. Bill PA, Vigonius U, Pohlmann H. A double blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res 1997; 27: 195-204.

  10. Sachdeo R, Beydoun A, Schachter S. Safety and efficacy of oxcarbazepine monotherapy Neurology 1998; 50: A200.

  11. Scheife RT. Progress in the treatment of epilepsy. Pharmacotherapy 2000; 20(8): 129S-199S.

  12. Moshé SL. Special considerations in treating children with epilepsy pharmacotherapy 2000; 20(8): 171S-177S.

  13. Armijo JA, Valdizan EM, De las Cuevas I, Cuadrado A. Avances en la fisiopatología de la epileptogenesis: aspectos moleculares. Rev Neurol 2002; 34(5): 409-29.

  14. National Institute for Clinical Excellence. Newer drugs for epilepsy in adults. Technology appraisal guidance 76. Marzo 2004: 4-32.

  15. French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, et al. Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy Neurology 2004; 62: 1261-73.

  16. Bill PA, Vigonius U, Pohlmann H, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res 1997; 27: 195-204.

  17. Christe W, Kramer G, Vigonius U, et al. A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res 1997; 26: 451-60.

  18. Dam M, Ekberg R, Loyning Y, et al. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989; 3 :70-6.

  19. Schachter SC, Vazquez B, Fisher RS. Oxcarbazepine; Double-blind randomized, placebo-controlled, monotherapy trial for partial seizures. Neurology 1999; 52: 732-7.

  20. Nagel RG. Nuevos tratamientos en epilepsia. Neurologia 2004; Suppl. 2: 22-7.




2020     |     www.medigraphic.com